Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...
the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Oregon Health & Science University, Portland, Oregon, United States
Royal Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
Soi Lee, Seoul, Korea, Republic of
Konkuk University Medical Center, Seoul, Korea, Republic of
Haseki Training and Research Hospital, Istanbul, Sultangazi, Turkey
Poznan University of Medical Sciences, Poznań, Poland
Wolfson medical center, H̱olon, Israel
Aarhus University Hospital, Aarhus, Central Denmark Region, Denmark
Aalborg University Hospital, Aalborg, North Denmark Region, Denmark
Dr sana aslam, Abbottabad, Khyber Pakhtun Khwaa, Pakistan
Sana aslam, Abbottābād, Khyber Pakhtun Khwa, Pakistan
Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.